secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2024-04-30T23:59:59+00:00
Accession:  0001367644-24-000055
Event type: debt
Sentiment:  negative
Materiality: 0.75
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions amends credit facility; revolver cut to $270M, interest margins raised
--------------------------------------------------------------------------------

- Revolving commitments reduce to $270M through July 30, then $225M, and $200M after Oct 31, 2024.
- Interest margins increase: Base Rate loans from 5% to 7%, SOFR/Eurocurrency from 6.5% to 8.5%.
- Company must raise at least $85M in equity or unsecured debt by July 31, 2024 (may be reduced by asset sale proceeds).
- 100% of net proceeds from certain dispositions must prepay revolver (up to $85M); excess applies to term loan.
- New monthly minimum EBITDA, maximum capex, and minimum liquidity covenants added through 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000055/0001367644-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764424000055/ebs-20240429.htm
  HTML page:      https://secwatch.observer/filing/0001367644-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer